• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    11 Health Care Stocks Moving In Wednesday's Pre-Market Session

    10/5/22 8:29:38 AM ET
    $APDN
    $ATXI
    $AUTL
    $AYTU
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APDN alert in real time by email

    Gainers

    • Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million.
    • SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 9.09% to $0.84. The market value of their outstanding shares is at $36.1 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock increased by 9.06% to $0.11. The company's market cap stands at $8.7 million.
    • Aytu BioPharma (NASDAQ:AYTU) shares increased by 8.38% to $0.22. The market value of their outstanding shares is at $13.7 million.
    • BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 7.74% to $0.33. The market value of their outstanding shares is at $12.4 million.

    Losers

    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock fell 24.2% to $5.6 during Wednesday's pre-market session. The company's market cap stands at $246.2 million.
    • Avenue Therapeutics (NASDAQ:ATXI) shares decreased by 21.38% to $11.4. The market value of their outstanding shares is at $16.8 million.
    • Autolus Therapeutics (NASDAQ:AUTL) stock fell 15.7% to $2.31. The market value of their outstanding shares is at $210.0 million.
    • Applied DNA Sciences (NASDAQ:APDN) stock fell 11.19% to $1.35. The company's market cap stands at $17.3 million.
    • GBS (NASDAQ:GBS) stock decreased by 10.93% to $0.49. The company's market cap stands at $7.2 million.
    • NantHealth (NASDAQ:NH) shares declined by 8.3% to $0.22. The company's market cap stands at $25.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $ATXI
    $AUTL
    $AYTU

    CompanyDatePrice TargetRatingAnalyst
    Autolus Therapeutics plc
    $AUTL
    2/17/2026$9.00Buy
    H.C. Wainwright
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    Aytu BioPharma Inc.
    $AYTU
    7/1/2025$8.00Buy
    Lake Street
    Aytu BioPharma Inc.
    $AYTU
    6/30/2025$12.00Buy
    Ascendiant Capital Markets
    SAB Biotherapeutics Inc.
    $SABS
    5/14/2025$10.00Buy
    H.C. Wainwright
    Autolus Therapeutics plc
    $AUTL
    11/18/2024$7.00 → $7.60Neutral → Buy
    Goldman
    Bionano Genomics Inc.
    $BNGO
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $APDN
    $ATXI
    $AUTL
    $AYTU
    SEC Filings

    View All

    SAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/10/26 7:35:30 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by SAB Biotherapeutics Inc.

    10-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/9/26 5:10:24 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

    2/23/26 4:06:15 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Disbrow Jarrett bought $24,999 worth of shares (16,666 units at $1.50), increasing direct ownership by 130% to 29,462 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    6/10/25 3:06:06 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Disbrow Joshua R. bought $99,999 worth of shares (66,666 units at $1.50), increasing direct ownership by 77% to 153,257 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    6/10/25 3:04:30 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    3/3/25 1:35:04 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

    Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action o

    3/10/26 7:31:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

    Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142's favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutica

    3/9/26 5:16:37 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 18 shares, decreasing direct ownership by 3% to 644 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:31:45 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 3 shares, decreasing direct ownership by 1% to 260 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:29:36 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 6 shares, decreasing direct ownership by 2% to 263 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:28:24 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on SAB BIO with a new price target

    Leerink Partners initiated coverage of SAB BIO with a rating of Outperform and set a new price target of $7.00

    9/17/25 8:03:24 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Leadership Updates

    Live Leadership Updates

    View All

    Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

    SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics

    2/27/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 4:32:31 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $ATXI
    $AUTL
    $AYTU
    Financials

    Live finance-specific insights

    View All

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

    Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patientsLeadership team bolstered to support next phase of growth and optimization of business operationsConference call to be held today at 8:30 am EST / 1:30 pm GMT; conference call participants should p

    11/12/25 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

    SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at htt

    10/30/25 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials